Know Cancer

or
forgot password

A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic Expanded Haploidentical Natural Killer (NK) Cells in Patients Treated With High Dose Melphalan Chemotherapy and Autologous Stem Cell Transplantation for a Multiple Myeloma


Phase 1/Phase 2
N/A
N/A
Open (Enrolling)
Both
Multiple Myeloma

Thank you

Trial Information

A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic Expanded Haploidentical Natural Killer (NK) Cells in Patients Treated With High Dose Melphalan Chemotherapy and Autologous Stem Cell Transplantation for a Multiple Myeloma


Inclusion Criteria:



- > 18 years, with multiple myeloma and indication for an autologous HSCT

- Available related haploidentical donor

- Written informed consent

Exclusion Criteria:

- Patients scheduled for autologous/allogeneic tandem HSCT

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety of expanded NK cell infusion

Outcome Time Frame:

One year after infusion.

Safety Issue:

Yes

Principal Investigator

Martin Stern, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dep. of Hematology, Petersgraben 4, CH-4031 Basel

Authority:

Switzerland: Swissmedic

Study ID:

NK_MM_01

NCT ID:

NCT01040026

Start Date:

December 2010

Completion Date:

October 2017

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location